Onchilles Pharma Presents New Data at AACR 2025 on N17350
25 Apr 2025 //
BUSINESSWIRE
Onchilles Advances ELANE Pathway Pan-Cancer Therapeutics
13 Jan 2025 //
BUSINESSWIRE
Onchilles Pharma Presents Data on NEU-002 for ELANE Pathway at SITC
07 Nov 2024 //
BUSINESSWIRE
Onchilles Pharma To Present NEU-002 Program Data At SITC 2024
04 Oct 2024 //
BUSINESSWIRE
Onchilles Pharma Presents N17350, N17465 Preclinical Data at AACR 2024
10 Apr 2024 //
BUSINESSWIRE
Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350
03 Nov 2023 //
BUSINESSWIRE
Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023
27 Sep 2023 //
BUSINESSWIRE
Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350
19 Apr 2023 //
BUSINESSWIRE
Onchilles Announces Presentation of Preclinical Data for N17350 at AACR 2023
14 Mar 2023 //
BUSINESSWIRE
Onchilles Nominates Drug Development Candidate Leveraging Neutrophil Biology
12 Dec 2022 //
BUSINESSWIRE
Onchilles Pharma Appoints Christopher Twitty, Chief Scientific Officer
26 Oct 2021 //
BUSINESSWIRE